Pharma, Non-Profits Ally To Advance TB Drug Combinations

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is taking two TB drug combinations into Phase II clinical trials to see if one or both of the regimens can effectively treat the disease with a shorter duration of therapy, reducing the burden on both patients and health care systems in resource-constrained countries where TB is most prevalent.

PAN-TB, which announced a joint development agreement on 17 August, is a collaboration between the philanthropic, non-profit and private sectors that aims to develop better treatments for all forms of TB, including drug-susceptible and drug-resistant TB. Johnson & Johnson’s Janssen Pharmaceutica NV, Otsuka Pharmaceutical Co. Ltd